STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Guardant Health Director Meghan V. Joyce received new equity compensation grants on June 18, 2025, consisting of:

  • Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57, fully vesting after one year on June 18, 2026 (or next annual stockholders meeting if earlier). The options expire on June 18, 2035.
  • Restricted Stock Units (RSUs): 4,203 RSUs granted at $0 exercise price, with the same one-year vesting schedule as the stock options.

This Form 4 filing, signed by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combination of options and RSUs aligns the director's interests with shareholders while providing both upside potential through options and guaranteed value through RSUs, subject to vesting requirements.

Meghan V. Joyce, Direttrice di Guardant Health, ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 50,57$, con maturazione completa dopo un anno, il 18 giugno 2026 (o alla prossima assemblea annuale degli azionisti se precedente). Le opzioni scadono il 18 giugno 2035.
  • Unità di azioni vincolate (RSU): 4.203 RSU con prezzo di esercizio pari a 0$, con lo stesso calendario di maturazione di un anno delle opzioni su azioni.

Il modulo Form 4, firmato per procura dall’avvocato John G. Saia il 20 giugno 2025, rappresenta le consuete assegnazioni di compensi azionari per i direttori. La combinazione di opzioni e RSU allinea gli interessi della direttrice con quelli degli azionisti, offrendo sia un potenziale di guadagno tramite le opzioni sia un valore garantito tramite le RSU, subordinato ai requisiti di maturazione.

Meghan V. Joyce, Directora de Guardant Health, recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: 6.833 opciones para comprar acciones comunes a un precio de ejercicio de 50,57$, con consolidación total después de un año, el 18 de junio de 2026 (o en la próxima junta anual de accionistas si es antes). Las opciones expiran el 18 de junio de 2035.
  • Unidades de acciones restringidas (RSU): 4.203 RSU otorgadas con precio de ejercicio de 0$, con el mismo calendario de consolidación de un año que las opciones sobre acciones.

Este formulario Form 4, firmado por apoderado legal John G. Saia el 20 de junio de 2025, representa las concesiones estándar de compensación en acciones para directores. La combinación de opciones y RSU alinea los intereses de la directora con los de los accionistas, ofreciendo tanto potencial de ganancia a través de las opciones como valor garantizado mediante las RSU, sujeto a los requisitos de consolidación.

Guardant Health의 이사 Meghan V. Joyce는 2025년 6월 18일에 다음과 같은 새로운 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 행사가격 50.57달러로 보통주 6,833주를 구매할 수 있는 옵션으로, 1년 후인 2026년 6월 18일(또는 그보다 빠른 경우 다음 연례 주주총회) 완전 취득됩니다. 옵션 만료일은 2035년 6월 18일입니다.
  • 제한 주식 단위(RSU): 행사가격 0달러로 4,203 RSU가 부여되었으며, 스톡 옵션과 동일한 1년 취득 일정이 적용됩니다.

2025년 6월 20일 법정대리인 John G. Saia가 서명한 이 Form 4 제출은 이사 보상으로서 표준적인 주식 보상 부여를 나타냅니다. 옵션과 RSU의 조합은 이사의 이익을 주주와 일치시키면서, 옵션을 통한 상승 잠재력과 RSU를 통한 보장 가치를 취득 요건에 따라 제공합니다.

Meghan V. Joyce, administratrice de Guardant Health, a reçu de nouvelles attributions de rémunération en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options pour acheter des actions ordinaires à un prix d'exercice de 50,57 $, devenant entièrement acquises après un an, le 18 juin 2026 (ou à la prochaine assemblée annuelle des actionnaires si elle a lieu plus tôt). Les options expirent le 18 juin 2035.
  • Unités d'actions restreintes (RSU) : 4 203 RSU attribuées à un prix d'exercice de 0 $, avec le même calendrier d'acquisition d'un an que les options d'achat.

Ce dépôt du formulaire 4, signé par le mandataire John G. Saia le 20 juin 2025, représente des attributions standard de rémunération en actions pour les administrateurs. La combinaison d'options et de RSU aligne les intérêts de l'administratrice avec ceux des actionnaires, offrant à la fois un potentiel de hausse grâce aux options et une valeur garantie via les RSU, sous réserve des conditions d'acquisition.

Meghan V. Joyce, Direktorin von Guardant Health, erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 $, die nach einem Jahr am 18. Juni 2026 (oder bei der nächsten jährlichen Hauptversammlung, falls früher) vollständig unverfallbar werden. Die Optionen verfallen am 18. Juni 2035.
  • Restricted Stock Units (RSUs): 4.203 RSUs mit einem Ausübungspreis von 0 $, mit dem gleichen einjährigen Unverfallbarkeitszeitplan wie die Aktienoptionen.

Diese Form 4 Einreichung, unterzeichnet vom Bevollmächtigten John G. Saia am 20. Juni 2025, stellt standardmäßige Aktienvergütungszuteilungen für Direktoren dar. Die Kombination aus Optionen und RSUs richtet die Interessen der Direktorin mit denen der Aktionäre aus und bietet sowohl Aufwärtspotenzial durch Optionen als auch garantierten Wert durch RSUs, vorbehaltlich der Unverfallbarkeitsanforderungen.

Positive
  • None.
Negative
  • None.

Meghan V. Joyce, Direttrice di Guardant Health, ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 50,57$, con maturazione completa dopo un anno, il 18 giugno 2026 (o alla prossima assemblea annuale degli azionisti se precedente). Le opzioni scadono il 18 giugno 2035.
  • Unità di azioni vincolate (RSU): 4.203 RSU con prezzo di esercizio pari a 0$, con lo stesso calendario di maturazione di un anno delle opzioni su azioni.

Il modulo Form 4, firmato per procura dall’avvocato John G. Saia il 20 giugno 2025, rappresenta le consuete assegnazioni di compensi azionari per i direttori. La combinazione di opzioni e RSU allinea gli interessi della direttrice con quelli degli azionisti, offrendo sia un potenziale di guadagno tramite le opzioni sia un valore garantito tramite le RSU, subordinato ai requisiti di maturazione.

Meghan V. Joyce, Directora de Guardant Health, recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: 6.833 opciones para comprar acciones comunes a un precio de ejercicio de 50,57$, con consolidación total después de un año, el 18 de junio de 2026 (o en la próxima junta anual de accionistas si es antes). Las opciones expiran el 18 de junio de 2035.
  • Unidades de acciones restringidas (RSU): 4.203 RSU otorgadas con precio de ejercicio de 0$, con el mismo calendario de consolidación de un año que las opciones sobre acciones.

Este formulario Form 4, firmado por apoderado legal John G. Saia el 20 de junio de 2025, representa las concesiones estándar de compensación en acciones para directores. La combinación de opciones y RSU alinea los intereses de la directora con los de los accionistas, ofreciendo tanto potencial de ganancia a través de las opciones como valor garantizado mediante las RSU, sujeto a los requisitos de consolidación.

Guardant Health의 이사 Meghan V. Joyce는 2025년 6월 18일에 다음과 같은 새로운 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 행사가격 50.57달러로 보통주 6,833주를 구매할 수 있는 옵션으로, 1년 후인 2026년 6월 18일(또는 그보다 빠른 경우 다음 연례 주주총회) 완전 취득됩니다. 옵션 만료일은 2035년 6월 18일입니다.
  • 제한 주식 단위(RSU): 행사가격 0달러로 4,203 RSU가 부여되었으며, 스톡 옵션과 동일한 1년 취득 일정이 적용됩니다.

2025년 6월 20일 법정대리인 John G. Saia가 서명한 이 Form 4 제출은 이사 보상으로서 표준적인 주식 보상 부여를 나타냅니다. 옵션과 RSU의 조합은 이사의 이익을 주주와 일치시키면서, 옵션을 통한 상승 잠재력과 RSU를 통한 보장 가치를 취득 요건에 따라 제공합니다.

Meghan V. Joyce, administratrice de Guardant Health, a reçu de nouvelles attributions de rémunération en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options pour acheter des actions ordinaires à un prix d'exercice de 50,57 $, devenant entièrement acquises après un an, le 18 juin 2026 (ou à la prochaine assemblée annuelle des actionnaires si elle a lieu plus tôt). Les options expirent le 18 juin 2035.
  • Unités d'actions restreintes (RSU) : 4 203 RSU attribuées à un prix d'exercice de 0 $, avec le même calendrier d'acquisition d'un an que les options d'achat.

Ce dépôt du formulaire 4, signé par le mandataire John G. Saia le 20 juin 2025, représente des attributions standard de rémunération en actions pour les administrateurs. La combinaison d'options et de RSU aligne les intérêts de l'administratrice avec ceux des actionnaires, offrant à la fois un potentiel de hausse grâce aux options et une valeur garantie via les RSU, sous réserve des conditions d'acquisition.

Meghan V. Joyce, Direktorin von Guardant Health, erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 $, die nach einem Jahr am 18. Juni 2026 (oder bei der nächsten jährlichen Hauptversammlung, falls früher) vollständig unverfallbar werden. Die Optionen verfallen am 18. Juni 2035.
  • Restricted Stock Units (RSUs): 4.203 RSUs mit einem Ausübungspreis von 0 $, mit dem gleichen einjährigen Unverfallbarkeitszeitplan wie die Aktienoptionen.

Diese Form 4 Einreichung, unterzeichnet vom Bevollmächtigten John G. Saia am 20. Juni 2025, stellt standardmäßige Aktienvergütungszuteilungen für Direktoren dar. Die Kombination aus Optionen und RSUs richtet die Interessen der Direktorin mit denen der Aktionäre aus und bietet sowohl Aufwärtspotenzial durch Optionen als auch garantierten Wert durch RSUs, vorbehaltlich der Unverfallbarkeitsanforderungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Joyce Meghan V.

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Meghan Verena Joyce 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Meghan Joyce receive at Guardant Health (GH) in June 2025?

Meghan Joyce received 6,833 stock options with an exercise price of $50.57 on June 18, 2025. These options will fully vest on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever comes earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to GH director Meghan Joyce?

Meghan Joyce was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is Meghan Joyce's role at Guardant Health (GH)?

According to the Form 4 filing, Meghan Joyce serves as a Director on Guardant Health's Board of Directors. This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What was the total value of equity compensation granted to GH director Meghan Joyce in June 2025?

The Form 4 shows that Meghan Joyce received two equity grants on June 18, 2025: 6,833 stock options with a strike price of $50.57 and 4,203 Restricted Stock Units (RSUs). Both grants were listed with a price of $0, as they are compensation grants. The actual value would depend on GH's stock price at the time of grant.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

6.01B
118.13M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO